Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03574571 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT03574571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03574571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 19, 2018
Completion date
April 1, 2027
Enrollment
732 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer